Answers are grounded in this paper and cite their sources.
Over the past decades, poly(ADP-ribose) polymerase inhibitors (PARPis) have reshaped the treatment of multiple solid tumors, including ovarian, breast, pancreatic, and prostate carcinomas, becoming the first-line maintenance therapy following chemotherapy in tumors harboring defects in the homologous recombination (HR) repair pathway, most notably through BRCA1/2 gene mutations. This review traces the development of PARPis from the seminal discovery of PARP enzymes to the clinical approval of different classes of PARPis, discussing their classification according to the mechanisms of action and isoform selectivity. We then discuss the molecular determinants of response, including BRCA1/2 mutation type and location, alterations in other HR repair genes, and functional HR deficiency biomarkers, together with HR-independent responses. Further, this review summarizes the pivotal Phase III trials supporting the use of PARPis across different tumor types and regardless of their HR status, and how clinical data has led to the restriction or withdrawal of several later-line indications, while supporting PARPi use in earlier disease stages. Lastly, we examine the mechanisms of acquired resistance and the pharmacological strategies to overcome it, including combinations with immune checkpoint inhibitors and inhibitors of the DNA damage response pathway, and the combinatorial opportunities offered by the newly developed PARP1-selective inhibitors. Overall, this review underscores the clinical impact of PARP inhibition in cancer therapy and highlights the holistic stratification of patients based on genomic and functional assays as key to maximizing the therapeutic potential of PARPi.
No takes yet. Share an insight, caveat, or question.
Granato et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: